Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids
- 1st Edition - April 4, 2017
- Authors: Surendra Nimesh, Ramesh Chandra, Nidhi Gupta
- Language: English
- Hardback ISBN:9 7 8 - 0 - 0 8 - 1 0 0 5 5 7 - 6
- eBook ISBN:9 7 8 - 0 - 0 8 - 1 0 0 5 6 3 - 7
Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids addresses several issues related to safe and effective delivery of nucleic acids (NAs) using nanoparti… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids addresses several issues related to safe and effective delivery of nucleic acids (NAs) using nanoparticles. A further emphasis would be laid on the mechanism of delivery of NAs, the barriers encountered and the strategies adapted to combat them. An exhaustive account of the advantages as well shortcomings of all the delivery vectors being employed in delivery of various NAs will be provided. On final note the regulatory aspects of nanoparticles mediated NA would be discussed, with focus on their clinical relevance.
The design and development of nucleic acid-based therapeutics for the treatment of diseases arising from genetic abnormalities has made significant progress over the past few years. NAs have been widely explored for the treatment of cancer and infectious diseases or to block cell proliferation and thereby caused diseases. Advances in synthetic oligonucleotide chemistry resulted in synthesis of NAs that are relatively stable in in vivo environments. However, cellular targeting and intracellular delivery of NAs still remains a challenge. Further development of NA-based therapeutics depends on the progress of safe and effective carriers for systemic administration. Nanomedicine has facilitated availability of vectors with diminished cytotoxicity and enhanced efficacy which are rapidly emerging as systems of choice. These vectors protect NAs from enzymatic degradation by forming condensed complexes along with targeted tissue and cellular delivery. During the past few years, a myriad reports have appeared reporting delivery of NAs mediated by nanoparticles. This book will provide an overview of nanoparticles being employed in the in vitro and in vivo delivery of therapeutically relevant NAs like DNA, siRNA, LNA, PNA, etc.
- Provides a complete overview of the applicatiosn of nanomedicine in the delivery of nucleic acids, from characterization of nanoparticles, to in vitro and in vivo studies
- Discusses delivery issues of less well explored nucleic acids, like PNAs, Ribozymes, DNAzymes, etc.
- Summarizes the current state of research in nucleic acid delivery and underscores the future of nanomedicine in this field
Professors and graduate students in therapeutic nanomedicine; researchers in nanomedicine and nucleic acids
1. Nanomedicine for delivery of therapeutic molecules
- 1.1. Introduction
- 1.2. Properties of nanoparticles
- 1.3. Polymeric nanoparticles
- 1.4. Nanoparticle-based strategies for overcoming in vitro and in vivo barriers
- 1.5. Book compilation
2. Nanoparticles as nucleic acid delivery vectors
- 2.1. Introduction
- 2.2. Challenges and barriers to the nucleic acid delivery
- 2.3. Vectors in nucleic acid delivery
- 2.4. Nanoparticles as nonviral nucleic acid delivery vectors
- 2.5. Conclusion and future prospects
3. Methods for characterization of nanoparticles
- 3.1. Introduction and challenges in nanoparticle characterization
- 3.2. Techniques and approaches to nanoparticle characterization
- 3.3. Stability evaluation of nanoparticles
- 3.4. Sterility assessment of nanoparticles
4. Nanoparticles for DNA delivery
- 4.1. Introduction
- 4.2. Low molecular weight linear polyethylenimine
- 4.3. High molecular weight linear polyethylenimine
- 4.4. Low molecular weight branched polyethylenimine
- 4.5. High molecular weight branched polyethylenimine
5. Nanoparticles for siRNA-mediated gene silencing
- 5.1. Introduction
- 5.2. Chitosan
- 5.3. Polyethylenimine
- 5.4. Poly-l-lysine
- 5.5. Dendrimers
- 5.6. Cyclodextrins
- 5.7. Poly(lactic-co-glycolic) acid
6. Nanoparticles for locked nucleic acid delivery
- 6.1. Introduction
- 6.2. Locked nucleic acids: structure
- 6.3. Locked nucleic acids: hybridization and conformation properties
- 6.4. Serum stability and nuclease resistance
- 6.5. Delivery and toxicity
- 6.6. Therapeutic applications of locked nucleic acids
- 6.7. Nanoparticle-mediated delivery of locked nucleic acid and locked nucleic acid-modified oligonucleotides
- 6.8. Conclusion and future prospects
7. Nanoparticles for ribozymes delivery
- 7.1. Introduction
- 7.2. Types of ribozymes
- 7.3. Ribozymes and their limitations
- 7.4. Selection of the target gene
- 7.5. Stability of ribozymes
- 7.6. Delivery of ribozymes
- 7.7. Applications of RNA nanoparticles emphasizing ribozymes
- 7.8. Conclusion and future prospects
8. Nanoparticles for DNAzymes delivery
- 8.1. Introduction
- 8.2. DNAzymes
- 8.3. The 10–23 DNAzymes
- 8.4. The 8–17 DNAzymes
- 8.5. Mechanism of DNAzymes
- 8.6. Advantages of DNAzymes
- 8.7. Stability of DNAzymes
- 8.8. Application of DNAzymes
- 8.9. DNAzyme delivery via metallic and polymeric nanoparticles
- 8.10. Conclusion and future prospects
9. Pharmacokinetics and biodistribution of the nanoparticles
- 9.1. Introduction
- 9.2. Pharmacokinetics of nanoparticles
- 9.3. Generalized pharmacokinetic profile of various nanoparticles
- 9.4. Challenges and future prospects
- 9.5. Conclusions
10. Nanotoxicology: Evaluation of toxicity potential of nanoparticles
- 10.1. Introduction
- 10.2. Size of nanoparticles
- 10.3. Dose-dependent toxicity
- 10.4. Nondosage-dependent actions/route
- 10.5. Surface area-dependent toxicity
- 10.6. Concentration-dependent toxicity
- 10.7. Particle chemistry and crystalline structure-dependent toxicity
- 10.8. Aspect ratio-dependent toxicity
- 10.9. Surface coating and functions attributed
- 10.10. Risk management of nanotechnology-specific aspects
- 10.11. Conclusion and future prospects
11. Regulatory aspects of nanoparticulate mediated nucleic acid delivery systems
- 11.1. Introduction
- 11.2. Issues related with nanoparticle mediated nucleic acid delivery systems
- 11.3. Current approaches for regulating pharmaceutical nanoparticles
12. Clinical studies and future prospects
- 12.1. Introduction
- 12.2. Regulatory pathways in the process of clinical trials
- 12.3. Barriers in the progress of clinical trials
- 12.4. Ethical concerns in clinical trials
- 12.5. Nanotherapeutics in clinical trials
- 12.6. Conclusion
- No. of pages: 256
- Language: English
- Edition: 1
- Published: April 4, 2017
- Imprint: Woodhead Publishing
- Hardback ISBN: 9780081005576
- eBook ISBN: 9780081005637
SN
Surendra Nimesh
Dr. Surendra Nimesh did PhD in nanotechnology from Dr. B.R. Ambedkar Center for Biomedical Science Research, University of Delhi and CSIR-Institute of Genomics and Integrative Biology, Delhi, India. He did postdoctorate at Ecole Polytechnique of Montreal, Montreal; Clinical Research Institute of Montreal, Montreal and Health Canada, Ottawa, Canada. He has published several research and review articles and authored/coauthored seven books that includes two Elsevier books: The Design and Development of Novel Drugs and Vaccines (2021) and Gene Therapy: Potential Applications of Nanotechnology (2013). He is an internationally recognized expert of nanotechnology for biological applications with specialization in drug and gene delivery.
Affiliations and expertise
Professor, Department of Biotechnology, Central University of Rajasthan, Ajmer, India; Professor (Adjunct), Department of Biomedical Science, Maharaja Surajmal Brij University, Bharatpur, India.RC
Ramesh Chandra
Affiliations and expertise
Ambedkar Center for Biomedical Research & Department of Chemistry, University of Delhi, IndiaNG
Nidhi Gupta
Dr. Nidhi Gupta received PhD degree in virology from the National Institute of Immunology and Jawaharlal Nehru University, New Delhi, India. She did doctoral research at Clinical Research Institute of Montreal, Montreal, and McGill University, Montreal, Canada. She has several research and review articles to her credit along with three authored/coauthored books. Her field of interest includes catalytic nucleic acids, siRNA, antisense, and nanomedicine.
Affiliations and expertise
Professor, Department of Biotechnology, IIS (Deemed to be University), Jaipur, India